Table 3.

Five-year overall and cancer-specific survival estimates according to bladder cancer pathology

Characteristic1	5y-OS (95% CI)		P-value2	5y-CSS (95% CI)		P-value2
	Female	Male		Female	Male
Overall3
Total	0.49 (0.47–0.51)	0.56 (0.54–0.57)	<0.001	0.59 (0.57–0.61)	0.71 (0.70–0.72)	<0.001
UC	0.52 (0.50–0.54)	0.57 (0.56–0.58)	<0.001	0.62 (0.60–0.65)	0.72 (0.71–0.73)	<0.001
Non-UC	0.21 (0.15–0.27)	0.31 (0.26–0.36)	0.002	0.26 (0.20–0.33)	0.43 (0.37–0.48)	<0.001
Period 03
Total	0.49 (0.45–0.53)	0.56 (0.54–0.58)	<0.001	0.56 (0.52–0.59)	0.66 (0.64–0.68)	<0.001
UC	0.53 (0.49–0.57)	0.57 (0.55–0.59)	0.047	0.60 (0.56–0.64)	0.67 (0.65–0.70)	0.001
Non-UC	0.16 (0.09–0.25)	0.32 (0.23–0.40)	0.01	0.20 (0.12–0.30)	0.36 (0.27–0.45)	0.02
Period 13
Total	0.48 (0.44–0.51)	0.56 (0.54–0.58)	<0.001	0.58 (0.54–0.62)	0.72 (0.70–0.74)	<0.001
UC	0.50 (0.46–0.53)	0.57 (0.55–0.59)	<0.001	0.61 (0.57–0.64)	0.73 (0.71–0.75)	<0.001
Non-UC	0.24 (0.14–0.35)	0.27 (0.19–0.37)	0.40	0.31 (0.19–0.43)	0.40 (0.29–0.50)	0.15
Period 23
Total	0.51 (0.46–0.55)	0.54 (0.52–0.56)	0.003	0.64 (0.59–0.68)	0.73 (0.71–0.75)	<0.001
UC	0.54 (0.49–0.58)	0.56 (0.53–0.58)	0.07	0.67 (0.62–0.71)	0.75 (0.73–0.77)	<0.001
Non-UC	0.24 (0.14–0.35)	0.32 (0.23–0.40)	0.04	0.31 (0.19–0.44)	0.52 (0.42–0.61)	0.007

NA, not available; UC, urothelial carcinoma; SCC, squamous cell carcinoma; AC, adenocarcinoma; NET, neuroendocrine tumor; Undiff, undifferentiated carcinoma; non-UC, nonurothelial carcinoma; 5y-OS, 5-year overall survival estimate; 5y-CSS, 5-year cancer-specific survival estimate. Non-UC includes SCC, AC, NET, Undiff, Sarcoma, and Others.

¹Data analyzed by Kaplan–Meier method in 10,712 patients with complete information on sex, pathology, age, period, and observation period.

²P-values for log-rank tests in each period and stratified log-rank tests over all periods, comparing female and male patients with each pathology.

³Period: Total, 1954–2010; Period 0, 1954–1992; Period 1, 1993–2002; Period 2, 2003–2010.